Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy contract development and manufacturing organization (CDMO), has been selected to manufacture adeno-associated vectors (AAV) therapies using its suspension AAV Curator Platform under the California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC).
Andelyn Biosciences Partners with Grace Science to Advance GS-100
COLUMBUS, Ohio, Jan. 15, 2024 /PRNewswire/ -- Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Armatus Bio to accelerate manufacturing of their gene therapy treatment for Charcot-Marie-Tooth Type 1A (CMT1A), a rare genetic neurological disease associated with independence-limiting disability and risk of fatal complications that has no approved therapies today. The partnership will seek to maximize program efficiency and speed to clinical studies of this novel, precision approach.
COLUMBUS, Ohio, Dec. 18, 2023 /PRNewswire/ -- Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced that it has been selected by Ultragenyx (NASDAQ: RARE) to perform late-stage Process Performance Qualification (PPQ) manufacturing of the company's UX111 gene therapy for the potential treatment of Sanfilippo Syndrome (MPS IIIA).
Andelyn Biosciences, a company that develops and manufactures cell and gene therapies, opened its new manufacturing headquarters, the Andelyn Corporate Center (ACC), in the Innovation District in Columbus, OH. The newly constructed state-of-the-art and regulatory-compliant facility complements Andelyn’s two existing facilities in Columbus.
COLUMBUS, Ohio--(BUSINESS WIRE)--Andelyn Biosciences, a pioneer in the development and manufacturing of cell and gene therapies, today formally inaugurates its new manufacturing headquarters, the Andelyn Corporate Center (ACC), located in the Innovation District in Columbus, Ohio. The newly constructed state-of-the-art and regulatory-compliant facility complements Andelyn’s two existing facilities in Columbus. With 180,000 square feet of office, laboratory, and manufacturing space, the ACC more than triples Andelyn’s footprint, ensuring the company will have the space and capabilities to meet the growing demand for its cell and gene therapy services.
Andelyn Biosciences, a cell and gene therapy CDMO, unveiled a new manufacturing headquarters in Ohio, more than tripling its production footprint.
Battelle, Amplify, and Andelyn Biosciences, have won a seat on an eight-year, $149 million indefinite delivery, indefinite quantity (IDIQ) contract vehicle for the National Institute of Neurological Disorders and Stroke.
Three contract organizations based near the capital of Ohio are starting the year with a multimillion-dollar deal.
Andelyn Biosciences Inc., a patient-focused gene therapy Contract Development and Manufacturing Organization, will help the INADcure Foundation bring the first-ever gene therapy for the treatment of Infantile Neuroaxonal Dystrophy (INAD) to clinical trials.